|
시장보고서
상품코드
2018242
빌리루빈 검사 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 검사 방법별, 환자별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)Bilirubin Testing Market Size, Share & Trends Analysis Report By Product (Test Cartridges & Strips, Dedicated Blood Bilirubin Analyzers), By Testing, By Patient (Neonates), By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
빌리루빈 검사 시장 요약
세계의 빌리루빈 검사 시장 규모는 2025년에 21억 6,000만 달러로 추계되며, 2033년까지 29억 4,000만 달러에 달할 것으로 예측되고 있으며, 2026-2033년에 CAGR 4.04%로 성장할 것으로 전망되고 있습니다.
신생아 의료의 조기 진단 툴에 대한 긴급한 필요성과 간 관련 질환의 유병률 증가에 힘입어 시장은 변화의 시기를 맞이하고 있습니다.
최근에는 임상 시험에서 90% 이상의 민감도를 달성한 새로운 마이크로 유체 장치로 인해 POC(Point of Care) 검사로 큰 전환이 이루어지고 있습니다. 이러한 혁신은 만삭아의 약 60%에 영향을 미치는 신생아 황달 발생률의 증가와 비알코올성 지방간 질환(NAFLD)과 같은 만성 간질환의 전 세계적 급증에 의해 크게 촉진되고 있습니다.
진단 검사실에 자동화된 고처리량 분석기를 도입하는 등 업계 리더들의 전략적 움직임은 워크플로우를 간소화하고 결과 도출 시간을 몇 시간에서 몇 분으로 단축하고 있습니다. 이러한 발전은 미국소아과학회(AAP)와 같은 단체의 최신 임상 가이드라인에 의해 더욱 촉진되고 있습니다. 이 가이드라인은 핵황달을 예방하기 위해 보다 엄격한 선별검사 프로토콜을 제안하고 있으며, 이에 따라 빌리루빈 검사는 현대 소아과 의료에서 필수적인 표준으로 자리 잡고 있습니다.
2025년 7월, 한 파일럿 연구에서 빌리루빈 검사를 위한 새로운 마이크로 유체 기반 현장 진료(POC) 장치 개발이 보고되었습니다. 이 디바이스는 표준 검사실 방법과의 높은 상관관계(R2=0.986)를 보였으며, 임상적으로 중요한 빌리루빈 수치 분류에 있으며, 높은 민감도(90%)와 특이도(97%)를 보였습니다. 휴대용 광전자 감지 기술을 사용하여 설계된 이 장치는 기존의 실험실 환경 밖에서 정확하고 신속한 검사를 제공하기 위해 고안된 것으로, 특히 분산형 또는 자원이 제한된 환경에서 신생아 황달 선별검사 및 간 기능 평가에 유용합니다. 표본 크기가 작고 광범위한 임상 연구가 필요한 이 혁신 기술은 현장 진단의 확장을 지원하고 빌리루빈 검사에 대한 접근성을 향상시키며 시장의 분산형 및 신생아 진단 부문의 성장을 촉진할 것으로 보입니다.
시장에서 가장 중요한 발전 중 하나는 경피적 빌리루빈 측정(TcB) 및 스마트폰 기반 진단 애플리케이션의 급속한 보급입니다. 기존의 빌리루빈 수치는 침습적인 '발뒤꿈치 천자'를 통한 채혈을 통해 측정했으나, 이는 신생아에게 큰 고통을 주고 감염의 위험도 있습니다. 그러나 현재 시장은 피부를 통해 즉각적인 측정값을 제공하는 빛을 이용한 비침습적 센서로 전환하고 있습니다. 인공지능(AI)과 머신러닝에 대한 새로운 연구로 스마트폰으로 유아의 피부와 눈의 이미지를 촬영하여 임상 수준에 가까운 정확도로 빌리루빈 수치를 예측할 수 있는 1차원 컨볼루션 신경망(1차원 컨볼루션 신경망)이 도입되었습니다. 이러한 기술적 도약은 환자의 편의성을 향상시킬 뿐만 아니라 재택 모니터링 및 원격의료 분야로 시장 적용 범위를 확대하여 보호자와 의료진이 병원을 자주 방문하지 않고도 황달의 진행 상황을 추적할 수 있도록 합니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 빌리루빈 검사 시장 : 변수, 동향, 범위
제4장 빌리루빈 검사 시장 : 제품별 추정·동향 분석
제5장 빌리루빈 검사 시장 : 기술별 추정·동향 분석
제6장 빌리루빈 검사 시장 : 용도별 추정·동향 분석
제7장 빌리루빈 검사 시장 : 환자별 추정·동향 분석
제8장 빌리루빈 검사 시장 : 최종 사용별 추정·동향 분석
제9장 빌리루빈 검사 시장 : 지역별 추정·동향 분석
제10장 경쟁 구도
KSA 26.05.14Bilirubin Testing Market Summary
The global bilirubin testing market size was estimated at USD 2.16 billion in 2025 and is projected to reach USD 2.94 billion by 2033, growing at a CAGR of 4.04% from 2026 to 2033. The market is experiencing a transformative phase, driven by an urgent need for early diagnostic tools in neonatal care and the rising prevalence of liver-related diseases.
Recently, there is a significant pivot toward point-of-care (POC) testing, with new microfluidic devices achieving over 90% sensitivity in clinical trials. These innovations are largely propelled by the increasing incidence of neonatal jaundice, which affects nearly 60% of full-term infants, and the global surge in chronic liver conditions such as Nonalcoholic Fatty Liver Disease (NAFLD).
Strategic moves by industry leaders, including the integration of automated high-throughput analyzers in diagnostic labs, are streamlining workflows and reducing the time-to-result from hours to minutes. This evolution is further supported by updated clinical guidelines from organizations like the American Academy of Pediatrics (AAP), which advocate for more rigorous screening protocols to prevent kernicterus, thereby cementing bilirubin testing as a non-negotiable standard in modern pediatric healthcare.
In July 2025, a pilot study reported the development of a new microfluidic-based point-of-care device for bilirubin testing that demonstrated strong correlation (R2 = 0.986) with standard laboratory methods, along with high sensitivity (90%) and specificity (97%) in classifying clinically relevant bilirubin levels. Designed with portable optoelectronic sensing technology, the device aims to provide accurate, rapid testing outside traditional laboratory settings, particularly benefiting neonatal jaundice screening and liver function assessment in decentralized or resource-limited environments. Although validated on a small sample size and requiring broader clinical studies, the innovation supports the expansion of point-of-care diagnostics, increases accessibility to bilirubin testing, and is likely to drive growth in the decentralized and neonatal diagnostics segments of the market.
One of the most significant developments in the market scope is the rapid adoption of transcutaneous bilirubinometry (TcB) and smartphone-based diagnostic applications. Traditionally, bilirubin levels were measured via invasive "heel stick" blood draws, which cause significant distress to neonates and carry risks of infection. However, the market is now shifting toward light-based, non-invasive sensors that provide instantaneous readings through the skin. Emerging research into Artificial Intelligence (AI) and machine learning has introduced 1D Convolutional Neural Networks capable of analyzing smartphone images of an infant's skin or eyes to predict bilirubin levels with near-clinical accuracy. This technological leap not only enhances patient comfort but also expands the market's reach into home-based monitoring and remote healthcare settings, allowing parents and clinicians to track jaundice levels without frequent hospital visits.
Global Bilirubin Testing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global bilirubin testing market report based on product, technology, application, patient, end use, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Bilirubin Reagent Kits and Assay Consumables
- Calibrators and Quality Controls
- Test Cartridges and Strips
- Dedicated Blood Bilirubin Analyzers
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Laboratory-Based Testing
- POC Testing
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Neonatal Jaundice Screening and Monitoring
- Liver Function Testing (LFT)
- Hemolytic Disorders Assessment
- Routine & Pre-operative Health Screening
- Patient Outlook (Revenue, USD Million, 2021 - 2033)
- Neonates
- Pediatric Patients
- Adults
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & NICUs
- Diagnostic Laboratories
- Maternity and Neonatal Clinics
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Spain
- Italy
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Product
- 1.2.2. Technology
- 1.2.3. Application
- 1.2.4. Patients
- 1.2.5. End Use
- 1.3. Regional Scope
- 1.4. Estimates and Forecast Timeline
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.7. Details of primary research
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity flow analysis (Model 1)
- 1.9.1.1. Approach 1: Commodity flow approach
- 1.9.2. Volume price analysis (Model 2)
- 1.9.2.1. Approach 2: Volume price analysis
- 1.9.1. Commodity flow analysis (Model 1)
- 1.10. Research Scope and Assumptions
- 1.10.1. List of Secondary Sources
- 1.10.2. List of Primary Sources
- 1.10.3. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Bilirubin Testing Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Drivers Analysis
- 3.2.1.1. Increasing prevalence of neonatal jaundice and liver disorders
- 3.2.1.2. Rising adoption of point-of-care and decentralized diagnostic solutions
- 3.2.1.3. Continuous technological advancements improving accuracy and turnaround time
- 3.2.2. Market Restraints Analysis
- 3.2.2.1. Presence of Ambiguous Regulatory Framework
- 3.2.2.2. Limited reimbursement support
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Supply Chain Analysis
- 3.2.1. Market Drivers Analysis
- 3.3. Bilirubin Testing Market Analysis Tools
- 3.3.1. Porter's Analysis
- 3.3.1.1. Bargaining power of the suppliers
- 3.3.1.2. Bargaining power of the buyers
- 3.3.1.3. Threats of substitution
- 3.3.1.4. Threats from new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic and Social landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Legal landscape
- 3.3.1. Porter's Analysis
- 3.4. Pricing Analysis
Chapter 4. Bilirubin Testing Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Bilirubin Testing Market: Product Movement Analysis, USD Million, 2025 & 2033
- 4.3. Bilirubin Reagent Kits and Assay Consumables
- 4.3.1. Bilirubin Reagent Kits and Assay Consumables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Calibrators and Quality Controls
- 4.4.1. Calibrators and Quality Controls Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Test Cartridges and Strips
- 4.5.1. Test Cartridges and Strips Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Dedicated Blood Bilirubin Analyzers
- 4.6.1. Dedicated Blood Bilirubin Analyzers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Bilirubin Testing Market: Technology Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Bilirubin Testing Market: Testing Movement Analysis, USD Million, 2025 & 2033
- 5.3. Laboratories-Based Testing
- 5.3.1. Laboratories-Based Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. POC Testing
- 5.4.1. POC Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Bilirubin Testing Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Bilirubin Testing Market: Application Movement Analysis, USD Million, 2025 & 2033
- 6.3. Neonatal Jaundice Screening and Monitoring
- 6.3.1. Neonatal Jaundice Screening and Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Liver Function Testing (LFT)
- 6.4.1. Liver Function Testing (LFT) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Hemolytic Disorders Assessment/Cancer
- 6.5.1. Hemolytic Disorders Assessment/Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Routine & Pre-operative Health Screening
- 6.6.1. Routine & Pre-operative Health Screening Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Bilirubin Testing Market: Patients Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Bilirubin Testing Market: Patients Movement Analysis, USD Million, 2025 & 2033
- 7.3. Neonates
- 7.3.1. Neonates Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Pediatric Patients
- 7.4.1. Pediatric Patients Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Adults
- 7.5.1. Adults Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Bilirubin Testing Market: End Use Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Bilirubin Testing Market: End Use Movement Analysis, USD Million, 2025 & 2033
- 8.3. Hospitals & NICUs
- 8.3.1. Hospitals & NICUs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4. Diagnostic Laboratories
- 8.4.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Maternity and Neonatal Clinics
- 8.5.1. Maternity and Neonatal Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Others
- 8.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Bilirubin Testing Market: Regional Estimates & Trend Analysis
- 9.1. Bilirubin Testing Market Share, By Region, 2025 & 2033, USD Million
- 9.2. North America
- 9.2.1. North America Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.2.2. U.S.
- 9.2.2.1. Key Country Dynamics
- 9.2.2.2. Regulatory Landscape/Reimbursement Scenario
- 9.2.2.3. Competitive Insights
- 9.2.2.4. U.S. Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.2.3. Canada
- 9.2.3.1. Key Country Dynamics
- 9.2.3.2. Regulatory Landscape/Reimbursement Scenario
- 9.2.3.3. Competitive Insights
- 9.2.3.4. Canada Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.2.4. Mexico
- 9.2.4.1. Key Country Dynamics
- 9.2.4.2. Regulatory Landscape/Reimbursement Scenario
- 9.2.4.3. Competitive Insights
- 9.2.4.4. Mexico Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3. Europe
- 9.3.1. Europe Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.2. UK
- 9.3.2.1. Key Country Dynamics
- 9.3.2.2. Regulatory Landscape/Reimbursement Scenario
- 9.3.2.3. Competitive Insights
- 9.3.2.4. UK Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.3. Germany
- 9.3.3.1. Key Country Dynamics
- 9.3.3.2. Regulatory Landscape/Reimbursement Scenario
- 9.3.3.3. Competitive Insights
- 9.3.3.4. Germany Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.4. France
- 9.3.4.1. Key Country Dynamics
- 9.3.4.2. Regulatory Landscape/Reimbursement Scenario
- 9.3.4.3. Competitive Insights
- 9.3.4.4. France Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.5. Italy
- 9.3.5.1. Key Country Dynamics
- 9.3.5.2. Regulatory Landscape/Reimbursement Scenario
- 9.3.5.3. Competitive Insights
- 9.3.5.4. Italy Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.6. Spain
- 9.3.6.1. Key Country Dynamics
- 9.3.6.2. Regulatory Landscape/Reimbursement Scenario
- 9.3.6.3. Competitive Insights
- 9.3.6.4. Spain Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.7. Sweden
- 9.3.7.1. Key Country Dynamics
- 9.3.7.2. Regulatory Landscape/Reimbursement Scenario
- 9.3.7.3. Competitive Insights
- 9.3.7.4. Sweden Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.8. Denmark
- 9.3.8.1. Key Country Dynamics
- 9.3.8.2. Regulatory Landscape/Reimbursement Scenario
- 9.3.8.3. Competitive Insights
- 9.3.8.4. Denmark Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.9. Norway
- 9.3.9.1. Key Country Dynamics
- 9.3.9.2. Regulatory Landscape/Reimbursement Scenario
- 9.3.9.3. Competitive Insights
- 9.3.9.4. Norway Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4. Asia Pacific
- 9.4.1. Asia Pacific Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.2. China
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Regulatory Landscape/Reimbursement Scenario
- 9.4.2.3. Competitive Insights
- 9.4.2.4. China Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.3. Japan
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Regulatory Landscape/Reimbursement Scenario
- 9.4.3.3. Competitive Insights
- 9.4.3.4. Japan Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.4. India
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Regulatory Landscape/Reimbursement Scenario
- 9.4.4.3. Competitive Insights
- 9.4.4.4. India Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.5. South Korea
- 9.4.5.1. Key Country Dynamics
- 9.4.5.2. Regulatory Landscape/Reimbursement Scenario
- 9.4.5.3. Competitive Insights
- 9.4.5.4. South Korea Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.6. Australia
- 9.4.6.1. Key Country Dynamics
- 9.4.6.2. Regulatory Landscape/Reimbursement Scenario
- 9.4.6.3. Competitive Insights
- 9.4.6.4. Australia Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.7. Thailand
- 9.4.7.1. Key Country Dynamics
- 9.4.7.2. Regulatory Landscape/Reimbursement Scenario
- 9.4.7.3. Competitive Insights
- 9.4.7.4. Thailand Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5. Latin America
- 9.5.1. Latin America Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.2. Brazil
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Regulatory Landscape/Reimbursement Scenario
- 9.5.2.3. Competitive Insights
- 9.5.2.4. Brazil Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.3. Argentina
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Regulatory Landscape/Reimbursement Scenario
- 9.5.3.3. Competitive Insights
- 9.5.3.4. Argentina Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6. Middle East and Africa
- 9.6.1. Middle East and Africa Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.2. Saudi Arabia
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Regulatory Landscape/Reimbursement Scenario
- 9.6.2.3. Competitive Insights
- 9.6.2.4. Saudi Arabia Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.3. UAE
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Regulatory Landscape/Reimbursement Scenario
- 9.6.3.3. Competitive Insights
- 9.6.3.4. UAE Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.4. South Africa
- 9.6.4.1. Key Country Dynamics
- 9.6.4.2. Regulatory Landscape/Reimbursement Scenario
- 9.6.4.3. Competitive Insights
- 9.6.4.4. South Africa Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.5. Kuwait
- 9.6.5.1. Key Country Dynamics
- 9.6.5.2. Regulatory Landscape/Reimbursement Scenario
- 9.6.5.3. Competitive Insights
- 9.6.5.4. Kuwait Bilirubin Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Recent Developments & Impact Analysis by Key Market Participants
- 10.2. Company Categorization
- 10.3. Global Company Market Share Analysis, 2025
- 10.4. Company Heat Map Analysis
- 10.5. Strategy Mapping
- 10.5.1. Expansion
- 10.5.2. Mergers & Acquisition
- 10.5.3. Partnerships & Collaborations
- 10.5.4. New Product Launches
- 10.5.5. Research And Development
- 10.6. Company Profiles
- 10.6.1. Abbott
- 10.6.1.1. Participant's Overview
- 10.6.1.2. Financial Performance
- 10.6.1.3. Product Benchmarking
- 10.6.1.4. Recent Developments
- 10.6.2. Beckman Coulter, Inc.
- 10.6.2.1. Participant's Overview
- 10.6.2.2. Financial Performance
- 10.6.2.3. Product Benchmarking
- 10.6.2.4. Recent Developments
- 10.6.3. Siemens Healthineers AG
- 10.6.3.1. Participant's Overview
- 10.6.3.2. Financial Performance
- 10.6.3.3. Product Benchmarking
- 10.6.3.4. Recent Developments
- 10.6.4. Randox Laboratories Ltd.
- 10.6.4.1. Participant's Overview
- 10.6.4.2. Financial Performance
- 10.6.4.3. Product Benchmarking
- 10.6.4.4. Recent Developments
- 10.6.5. SEKISUI Diagnostics
- 10.6.5.1. Participant's Overview
- 10.6.5.2. Financial Performance
- 10.6.5.3. Product Benchmarking
- 10.6.5.4. Recent Developments
- 10.6.6. Fortress Diagnostics
- 10.6.6.1. Participant's Overview
- 10.6.6.2. Financial Performance
- 10.6.6.3. Product Benchmarking
- 10.6.6.4. Recent Developments
- 10.6.7. Quidel Corporation
- 10.6.7.1. Participant's Overview
- 10.6.7.2. Financial Performance
- 10.6.7.3. Product Benchmarking
- 10.6.7.4. Recent Developments
- 10.6.8. Agappe Diagnostics Ltd.
- 10.6.8.1. Participant's Overview
- 10.6.8.2. Financial Performance
- 10.6.8.3. Product Benchmarking
- 10.6.8.4. Recent Developments
- 10.6.9. Nova Biomedical
- 10.6.9.1. Participant's Overview
- 10.6.9.2. Financial Performance
- 10.6.9.3. Product Benchmarking
- 10.6.9.4. Recent Developments
- 10.6.10. Radiometer Medical ApS
- 10.6.10.1. Participant's Overview
- 10.6.10.2. Financial Performance
- 10.6.10.3. Product Benchmarking
- 10.6.10.4. Recent Developments
- 10.6.1. Abbott
